Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus.
A number of approaches have been used in attempts to develop a safe and effective vaccine for respiratory syncytial virus (RSV) infection. This article describes an effective prophylactic intranasal gene transfer strategy utilizing chitosan-DNA nanospheres [the mucosal gene expression vaccine (MGXV)], containing a mixture of plasmid DNAs encoding RSV antigens. In a mouse model of RSV infection, a single administration of MGXV (25 microg/mouse) results in a significant reduction of viral titers and viral antigen load after acute RSV infection of these mice. MGXV-treated mice show no significant change in airway reactivity to methacholine and no apparent pulmonary inflammation. Together these results demonstrate the potential of MGXV against acute RSV infection.
Mohapatra
Shyam S
SS
Dept. of Internal Medicine, Div. of Allergy and Immunology, Joy McCann Culverhouse Airway Disease Research Center, University of South Florida College of Medicine/VA Hospital, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612, USA. smohapat@hsc.usf.edu
D000956:Antigens, Viral; D001672:Biocompatible Materials; D002648:Child; D002675:Child, Preschool; D002686:Chitin / Q000031:analogs & derivatives*; D048271:Chitosan; D004279:DNA, Viral / Q000235:genetics*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D009092:Mucous Membrane; D010957:Plasmids / Q000235:genetics; D018357:Respiratory Syncytial Virus Infections / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000235:genetics* / Q000472:pathogenicity; D019562:Viral Load; D014765:Viral Vaccines / Q000276:immunology*
D000956:Antigens, Viral; D001672:Biocompatible Materials; D004279:DNA, Viral; D014765:Viral Vaccines; D002686:Chitin; D048271:Chitosan